Targeting SOST using a small-molecule compound retards breast cancer bone metastasis

BACKGROUND: Breast cancer metastasis to the bone can be exacerbated by osteoporosis, is associated with poor long-term survival, and has limited therapeutic options. Sclerostin (SOST) is an endogenous inhibitor of bone formation, and an attractive target for treatment of osteoporosis. However, it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lisha, Zhang, Yixiao, Chen, Guanglei, Ji, Yaoting, Ma, Qingtian, Qiao, Xinbo, Wu, Sijin, Zhou, Lin, Bu, Jiawen, Zhu, Xudong, Zhang, Xiaoying, Jiang, Xiaofan, Liu, Chao, Li, Xinnan, Liu, Yang, Yang, Yongliang, Liu, Caigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798707/
https://www.ncbi.nlm.nih.gov/pubmed/36581888
http://dx.doi.org/10.1186/s12943-022-01697-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798707/
https://www.ncbi.nlm.nih.gov/pubmed/36581888
http://dx.doi.org/10.1186/s12943-022-01697-4

Ejemplares similares